$AZN $MRK Lynparza in 1L Maintenance BRCAm ovarian cancer data out in NEJM --> $CLVS $TSRO nejm.org/doi/full/10.10… PFS HR=0.30 One of the most amazing PFS curve this year!

🟢DESTINY-Breast04: standing ovation more than deserved👏. T-Dxd showed to improve PFS and OS in pretreated HER2-low (1+ and 2+ ISH -) #MBC patients vs TPC. "The ADC era has just begun also in HER2-low BC". These results speak for themselves. Camilla Lisanti #ASCO22 #BCAreporter

$PFE $MRK $SGEN Padcev + Keytruda in 1L urothelial EV-302, via Thomas Powles. Survival benefit irrespective of cisplatin eligibility or PD-L1 status. New SoC #ESMO23 $BCYC

After a standing ovation at #ESMO23, the EV-302 phase 3 trial of EV/pembro (vs platinum/gem) in 1L mUC by Tom Powles et al is published on NEJM. OS nearly doubled with the ADC/IO combo. Targeted chemo delivery keeps reshaping practice across tumor types. nejm.org/doi/full/10.10…

T-DXd is approved for the treatment of patients with ANY treatment-refractory HER2+ (IHC 3+) tumor, making of it the first agnostic ADC. Unlikely to be the last. Key priority: ensuring that HER2 testing is expanded across cancer types. Exciting times! fda.gov/drugs/resource…

🚨 Cancer of unknown primary (CUP) has long been a therapeutic challenge with poor outcomes. New data show that molecularly guided therapy and immunotherapy can improve survival, while ctDNA, methylation profiling, and AI-based pathology enable precision strategies. 📖

in 2L HER2+ metastatic breast cancer, in 10 years, from 2012 to 2022, we have reduced risk of progression and death by !!80%!! - Lapatinib + cape 6.4 months - TDM1 9.6 months - TDXd 29.1 months #ESMO25 Dr. Rupert Bartsch

A standing ovation moment at #ESMO25 In front of more than 9,000 cancer specialists and researchers, the Phase 3 RC48-C016 trial redefined the outlook for HER2-expressing urothelial cancer: Disitamab vedotin + Toripalimab nearly doubled overall survival over chemotherapy —

“Doctor, what is the right therapy for me?”. Lately, the answer to this Qx has become increasingly unclear among pts with ER+ MBC. We have CDKs, SERDs, PI3K-Akt-mTOR agents, ADCs, chemo— & insufficient biomarkers. Thanks Oncology News Central for the interview. oncologynewscentral.com/breast-cancer/…

Great slide (Bluestar Advisors) about progress across different cancers. They looked at OS improvement in 1st line patients and divided indications to blue ocean or red ocean based on magnitude of improvement. Biggest progress was in melanoma and renal cancer (PD1/CTLA4),

You send plasma from same patient for cell-free DNA testing to two different companies. In nearly all cases, you get different results from each. Data offer humbling reminder of imprecision of #PrecisionMedicine. ja.ma/2BfT8G4

More great stuff from Asher Mullard on genomics and drug development... Always worth reading/following. x.com/AsherMullard/s…

The many colors of a wasp’s microbiome. Just imagine what yours might look like... #microbiome #sciart #scicomm #wasps #microbialrainbow

So many pretty molecules (nearly 2/3 small molecules) approved in 2017. See 'em all here: cen.acs.org/articles/96/we…

One-shot immitation learning from noisy labeled data!

Beautiful visualization of daily temperature changes. The earth looks like a beating heart. x.com/severeweatherE…

Prediction of protein structure directly from DNA sequence is a holy grail of biology. Exciting new work from Mohammed AlQuraishi: biorxiv.org/content/early/… Different from other approaches (e.g., coevolution, simulations). Could maybe be combined with them for even greater accuracy.

Who designs better synthetic routes -- humans or computers? #Chemists test out computer-programmed #syntheses for the first time: ow.ly/7DnT30iIwM0

Very cool figure of 87 new and emerging molecular targets at #AACR18 biocentury.com/bc-innovations… via BioCentury

The future of clinical trials is site-less, hopes Kevin, Novartis, and many others, writes Elie Dolgin in Nature Reviews Drug Discovery rdcu.be/MK4d